1-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-1,4-diazepane

Catalog No. :
ACFQGA129
CAS No. :
231953-40-5
Molecular Formula :
C11H13ClF3N3
Molecular Weight :
279.69

IUPAC Name:1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-1,4-diazepane

1-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-1,4-diazepane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$144.00Login to see priceInquiryInquiry
1g95%$355.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-1,4-diazepane
IUPAC Name1-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-1,4-diazepane
MDL No.MFCD00238856
Molecular FormulaC11H13ClF3N3
Molecular Weight279.69
SMILESFC(C1=CN=C(N2CCNCCC2)C(Cl)=C1)(F)F
InChI KeyPKKLERQDFWUWNM-UHFFFAOYSA-N
SynonymBUTTPARK 33\06-20;1-[3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-1,4-DIAZEPANE;1-[3-CHLORO-5-(TRIFLUOROMETHYL)-2-PYRIDYL]-1,4-DIAZEPANE;1-[3-CHLORO-5-(TRIFLUOROMETHYL)PYRID-2-YL]-1,4-DIAZEPANE;1-[3-CHLORO-5-(TRIFLUOROMETHYL)PYRID-2-YL]HOMOPIPERAZINE;1-[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]hexahydro-1H-1,4-diazepine;TOSLAB 803433;1-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]-1,4-diazepane 97%
CAS No.231953-40-5

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301
Precautionary Statement(s)
P301+P310

Synthetic Route by SureRoute

1. ACFQGA129 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFQGA129 route product structure diagram
    ACFQGA129231953-40-5
Inquiry

2. ACFQGA129 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFQGA129 route product structure diagram
    ACFQGA129231953-40-5
Inquiry

Comments (0)